Everolimus depletes plaque macrophages, abolishes intraplaque neovascularization and improves survival in mice with advanced atherosclerosis.

CONCLUSIONS: Everolimus enhances features of plaque stability and counters cardiovascular complications in ApoE-/-Fbn1C1039G+/- mice, even when administered at a later stage of the disease.
PMID: 30590134 [PubMed - as supplied by publisher]

Source: Vascular Pharmacology - December 24, 2018 Category: Drugs & Pharmacology Authors: Kurdi A, Roth L, Van der Veken B, Van Dam D, De Deyn PP, De Doncker M, Neels H, De Meyer GRY, Martinet W Tags: Vascul Pharmacol Source Type: research